IQUIX
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IQUIX is an ophthalmic solution approved in 2004 by Santen for delivery via eye drops. The specific indication and mechanism of action are not publicly disclosed in available data, but the product represents a small-molecule therapeutic for ocular use.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30 intensity); career growth on this brand is likely constrained unless defensive strategies drive new opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IQUIX career opportunities are concentrated in Asia-Pacific (Japan, Singapore, Thailand), reflecting Santen's regional focus and the product's mature lifecycle stage. Roles emphasize vigilance, technical support, and field sales rather than growth development.
[Singapore] Global Safety Vigilance Risk Management Lead[Japan] Manager
Worked on IQUIX at Santen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.